ClinOhio Research Services Participates in TibuSHIELD Clinical Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
- kwillette95
- Jun 11
- 2 min read
Columbus, OH — May 23, 2025 — ClinOhio Research Services is proud to announce its participation in the TibuSHIELD study, a global Phase 2 clinical trial sponsored by Zura Bio. This study is evaluating the investigational therapy tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS)—a chronic, inflammatory skin disease with limited effective treatment options.
TibuSHIELD will assess the safety, tolerability, and efficacy of tibulizumab in approximately 180 adult participants over a 28-week period, including a 16-week primary efficacy phase and a 12-week safety follow-up. The study is being conducted at clinical research sites globally, including at ClinOhio Research.
“Hidradenitis suppurativa remains a difficult condition to manage, with many patients experiencing persistent disease activity despite currently available treatments,” said Alexa B. Kimball, MD, MPH, Professor of Dermatology at Harvard Medical School and President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center. “Studying tibulizumab represents an important opportunity to evaluate an investigational therapy designed to target multiple aspects of the inflammatory process in HS. We look forward to investigating this approach for individuals living with this challenging disease.”
Tibulizumab is a novel, humanized tetravalent dual-antagonist antibody, uniquely engineered to bind and neutralize both BAFF and IL-17A, two key cytokines involved in inflammatory pathways.
“The initiation of TibuSHIELD marks a key milestone in our mission to advance potentially differentiated therapies for patients with severe inflammatory diseases,” said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Zura Bio. “Tibulizumab’s dual mechanism of action offers a novel approach for the potential treatment of hidradenitis suppurativa. We remain committed to advancing clinical development with investigators, clinical sites, and the HS community.”
Tibulizumab is an investigational compound and has not been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.
About Zura Bio
Zura Bio is a clinical-stage immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with high unmet needs. Its pipeline includes candidates designed to optimize efficacy, safety, and dosing convenience by targeting key mechanisms of immune system imbalance.
About ClinOhio Research
ClinOhio Research Services is a dedicated clinical trial center committed to advancing science through innovative research and patient-centered care. With expertise in dermatology and clinical care, ClinOhio provides access to cutting-edge therapies for patients throughout Ohio.
For more information about the TibuSHIELD study, click here.
References
Comentarios